Chan Mi Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chan Mi Lee has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Pyoeng Gyun Choe
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
14 shared publications - Wan Beom Park
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
14 shared publications - Nam Joong Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
13 shared publications - Chang Kyung Kang
Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
10 shared publications - Hyeon Jae Jo
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
8 shared publications - Myoung-Don Oh
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Patient-Reported Outcomes After Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine Versus Staying on Oral Antiretroviral Therapy: A Prospective Korean Cohort Study
Shin DH, et al. J Korean Med Sci. 2027 Mar;42:e71. https://doi.org/10.3346/jkms.2027.42.e71
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Open AccessPatient-Reported Outcomes After Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine Versus Staying on Oral Antiretroviral Therapy: A Prospective Korean Cohort Study
Shin DH, et al. J Korean Med Sci. 2027 Mar;42:e71. https://doi.org/10.3346/jkms.2027.42.e71
- Top Cited PapersOpen Access
- 13 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2006-2015
Infections after bispecific antibodies in B-cell lymphomas
Bispecific antibodies (BsAbs) have expanded therapeutic options for patients with relapsed/refractory B-cell lymphomas, yet their use has introduced a distinct spectrum of infectious complications that remain poorly characterized. In the largest cohort study to date, to our knowledge, we evaluated 109 patients treated with CD20×CD3 BsAbs between 2016 and 2024 to assess the incidence, characteristics, and risk factors of infections. Over a median follow-up of 28.4 months, 134 infectious episodes were identified, 61.2% of which were grade ≥3. The median time to infection onset was 6.6 months, with bacterial infections occurring earliest (5.9 months), followed by fungal (7.0 months) and viral infections (8.3 months). Among the microbiologically defined infections, viral infections were the most common (61.1%), with severe acute respiratory syndrome coronavirus 2 and cytomegalovirus (CMV) being the leading causes. Of the 109 patients, 68 (62.4%) experienced at least 1 infectious episode and 41 (37.6%) had grade ≥3 infections. The cumulative incidence of infection steadily increased over 24 months, reaching 76.4% at 24 months. The cumulative incidence of CMV infection steadily increased over the first 12 months. Neutropenia (absolute neutrophil count <1.0 × 109/L) and hypogammaglobulinemia (immunoglobulin G level <400 mg/dL) were independent risk factors for all-grade infection, whereas hypogammaglobulinemia was the sole independent risk factor for grade 3 to 5 infection. Early corticosteroid use was not associated with an increased infection risk. In summary, this study provides a temporal map of infection dynamics and highlights underrecognized complications, such as CMV reactivation. Risk-adapted therapeutic approaches and refined supportive care strategies are warranted for patients with B-cell lymphomas treated with BsAbs.
- 13 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2006-2015
Top Cited PapersOpen AccessInfections after bispecific antibodies in B-cell lymphomas
Bispecific antibodies (BsAbs) have expanded therapeutic options for patients with relapsed/refractory B-cell lymphomas, yet their use has introduced a distinct spectrum of infectious complications that remain poorly characterized. In the largest cohort study to date, to our knowledge, we evaluated 109 patients treated with CD20×CD3 BsAbs between 2016 and 2024 to assess the incidence, characteristics, and risk factors of infections. Over a median follow-up of 28.4 months, 134 infectious episodes were identified, 61.2% of which were grade ≥3. The median time to infection onset was 6.6 months, with bacterial infections occurring earliest (5.9 months), followed by fungal (7.0 months) and viral infections (8.3 months). Among the microbiologically defined infections, viral infections were the most common (61.1%), with severe acute respiratory syndrome coronavirus 2 and cytomegalovirus (CMV) being the leading causes. Of the 109 patients, 68 (62.4%) experienced at least 1 infectious episode and 41 (37.6%) had grade ≥3 infections. The cumulative incidence of infection steadily increased over 24 months, reaching 76.4% at 24 months. The cumulative incidence of CMV infection steadily increased over the first 12 months. Neutropenia (absolute neutrophil count <1.0 × 109/L) and hypogammaglobulinemia (immunoglobulin G level <400 mg/dL) were independent risk factors for all-grade infection, whereas hypogammaglobulinemia was the sole independent risk factor for grade 3 to 5 infection. Early corticosteroid use was not associated with an increased infection risk. In summary, this study provides a temporal map of infection dynamics and highlights underrecognized complications, such as CMV reactivation. Risk-adapted therapeutic approaches and refined supportive care strategies are warranted for patients with B-cell lymphomas treated with BsAbs.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (17) , e129
Sero-Epidemiologic Study of Respiratory Syncytial Virus Infection in Korea
Na SH, et al. J Korean Med Sci. 2026 May;41:e129. https://doi.org/10.3346/jkms.2026.41.e129
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (17) , e129
Open AccessSero-Epidemiologic Study of Respiratory Syncytial Virus Infection in Korea
Na SH, et al. J Korean Med Sci. 2026 May;41:e129. https://doi.org/10.3346/jkms.2026.41.e129
- 4 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70736
Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis
Cytomegalovirus (CMV) infection remains a major contributor to CMV‐related and hematologic adverse outcomes in hematopoietic stem cell transplantation (HSCT) recipients. While letermovir has improved CMV prophylaxis strategies in this population, the clinical implications of low‐grade CMV DNAemia during letermovir prophylaxis remain uncertain. We retrospectively analyzed 255 HSCT recipients who received letermovir at a tertiary hospital in Korea. Patients were stratified into three groups based on the highest CMV DNAemia levels observed during letermovir prophylaxis: no DNAemia ( n = 72), low‐grade DNAemia (< 1000 IU/mL; n = 171), and high‐grade DNAemia (≥ 1000 IU/mL; n = 12). The association between low‐grade CMV DNAemia and clinical outcomes was assessed using a multivariate Cox proportional hazards model. Most low‐grade DNAemia cases were transient and resolved without antiviral therapy. Compared to no DNAemia, low‐grade CMV DNAemia was not associated with an increased risk of clinically significant CMV infection by Day 100 ( p = 0.262) or Day 365 ( p = 0.399). No significant associations were observed with engraftment failure ( p = 0.098), disease relapse ( p = 0.165), or all‐cause mortality ( p = 0.537). Our findings suggest that close monitoring may be sufficient for low‐grade DNAemia under letermovir prophylaxis.
- 4 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70736
Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis
Cytomegalovirus (CMV) infection remains a major contributor to CMV‐related and hematologic adverse outcomes in hematopoietic stem cell transplantation (HSCT) recipients. While letermovir has improved CMV prophylaxis strategies in this population, the clinical implications of low‐grade CMV DNAemia during letermovir prophylaxis remain uncertain. We retrospectively analyzed 255 HSCT recipients who received letermovir at a tertiary hospital in Korea. Patients were stratified into three groups based on the highest CMV DNAemia levels observed during letermovir prophylaxis: no DNAemia ( n = 72), low‐grade DNAemia (< 1000 IU/mL; n = 171), and high‐grade DNAemia (≥ 1000 IU/mL; n = 12). The association between low‐grade CMV DNAemia and clinical outcomes was assessed using a multivariate Cox proportional hazards model. Most low‐grade DNAemia cases were transient and resolved without antiviral therapy. Compared to no DNAemia, low‐grade CMV DNAemia was not associated with an increased risk of clinically significant CMV infection by Day 100 ( p = 0.262) or Day 365 ( p = 0.399). No significant associations were observed with engraftment failure ( p = 0.098), disease relapse ( p = 0.165), or all‐cause mortality ( p = 0.537). Our findings suggest that close monitoring may be sufficient for low‐grade DNAemia under letermovir prophylaxis.
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf255
Impact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea
Background: Anti-CD20 therapy has been associated with severe pneumonia in coronavirus disease 2019 (COVID-19) patients. This study aimed to evaluate the impact of anti-CD20 therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19–related outcomes using a nationwide cohort. Methods: We used the K-CoV-N database, integrating the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Adults (≥19 years) diagnosed with conditions warranting anti-CD20 therapy from January 2020 to December 2021 were included. Patients initiating rituximab (RTX) during the study period were defined as RTX users, whereas RTX nonusers were selected through propensity score matching. Logistic regression analyses were used to estimate the association between RTX use and SARS-CoV-2 infection, as well as COVID-19–related outcomes. Results: Among 1 548 038 patients requiring anti-CD20 therapy, 1 457 171 were vaccinated and 90 867 were unvaccinated. In the vaccinated group, RTX use was not significantly associated with an increased risk of SARS-CoV-2 infection (adjusted odds ratio [aOR] 1.75; 95% confidence interval [CI], .82–3.72; P = .149) but was linked to higher hospitalization for COVID-19 (aOR 2.64; 95% CI, 1.14–6.10; P = .024) and intensive care unit admission (aOR 10.89; 95% CI, 1.44–82.46; P = .021). In the unvaccinated group, RTX use showed no statistically significant associations with severe COVID-19 outcomes. Conclusions: Using a nationwide dataset, this study found that RTX use is associated with an increased risk of severe COVID-19 outcomes in vaccinated individuals. Despite rising vaccination rates, clinicians should carefully weigh the risks and benefits of anti-CD20 therapy during the COVID-19 pandemic.
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf255
Open AccessImpact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea
Background: Anti-CD20 therapy has been associated with severe pneumonia in coronavirus disease 2019 (COVID-19) patients. This study aimed to evaluate the impact of anti-CD20 therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19–related outcomes using a nationwide cohort. Methods: We used the K-CoV-N database, integrating the Korea Disease Control and Prevention Agency and the National Health Insurance Service. Adults (≥19 years) diagnosed with conditions warranting anti-CD20 therapy from January 2020 to December 2021 were included. Patients initiating rituximab (RTX) during the study period were defined as RTX users, whereas RTX nonusers were selected through propensity score matching. Logistic regression analyses were used to estimate the association between RTX use and SARS-CoV-2 infection, as well as COVID-19–related outcomes. Results: Among 1 548 038 patients requiring anti-CD20 therapy, 1 457 171 were vaccinated and 90 867 were unvaccinated. In the vaccinated group, RTX use was not significantly associated with an increased risk of SARS-CoV-2 infection (adjusted odds ratio [aOR] 1.75; 95% confidence interval [CI], .82–3.72; P = .149) but was linked to higher hospitalization for COVID-19 (aOR 2.64; 95% CI, 1.14–6.10; P = .024) and intensive care unit admission (aOR 10.89; 95% CI, 1.44–82.46; P = .021). In the unvaccinated group, RTX use showed no statistically significant associations with severe COVID-19 outcomes. Conclusions: Using a nationwide dataset, this study found that RTX use is associated with an increased risk of severe COVID-19 outcomes in vaccinated individuals. Despite rising vaccination rates, clinicians should carefully weigh the risks and benefits of anti-CD20 therapy during the COVID-19 pandemic.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (20)
Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies
Park T, et al. J Korean Med Sci. 2025 Feb;40:e86. https://doi.org/10.3346/jkms.2025.40.e86
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (20)
Open AccessIncidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies
Park T, et al. J Korean Med Sci. 2025 Feb;40:e86. https://doi.org/10.3346/jkms.2025.40.e86
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (4) , e88
Delayed Diagnosis of Imported Cystic Echinococcosis and Successful Treatment With Percutaneous Drainage and Albendazole in Korea: A Case Report
Choi WJ, et al. J Korean Med Sci. 2025 Jan;40(4):e88. https://doi.org/10.3346/jkms.2025.40.e88
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (4) , e88
Open AccessDelayed Diagnosis of Imported Cystic Echinococcosis and Successful Treatment With Percutaneous Drainage and Albendazole in Korea: A Case Report
Choi WJ, et al. J Korean Med Sci. 2025 Jan;40(4):e88. https://doi.org/10.3346/jkms.2025.40.e88
- Top Cited Papers
- 24 July 2024
- Published by Springer Nature in Nature
- Vol. 632 (8026) , 893-902
Blood culture-free ultra-rapid antimicrobial susceptibility testing
- 24 July 2024
- Published by Springer Nature in Nature
- Vol. 632 (8026) , 893-902
Top Cited PapersBlood culture-free ultra-rapid antimicrobial susceptibility testing
- 8 July 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (9) , 2327-2333
Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia
Background: When to perform echocardiography to rule out infective endocarditis (IE) in patients with viridans group streptococci (VGS) bloodstream infections (BSIs) is unclear. Objectives: We aimed to identify independent risk factors for IE in patients with VGS BSI. Methods: This retrospective study conducted at Seoul National University Hospital from January 2013 to December 2022 involved patients with VGS and nutritionally variant streptococcal BSI, excluding single positive blood cultures and polymicrobial BSI cases. Independent risk factors were identified by multivariate logistic regression and sensitivity analyses according to echocardiography results, VGS species or the inclusion of possible IE cases. Results: Of 845 VGS BSI cases, 349 were analysed and 86 IE cases were identified (24.6%). In the multivariate analysis, heart valve disease [adjusted odds ratio (aOR), 14.14, 95% CI, 6.14–32.58; P < 0.001], persistent bacteraemia (aOR, 5.12, 95% CI, 2.03–12.94; P = 0.001), age (per year, aOR, 0.98; 95% CI, 0.96–1.00; P = 0.015), solid cancer (aOR, 0.26; 95% CI, 0.13–0.53; P < 0.001) and haematologic malignancy (aOR, 0.04; 95% CI, 0.01–0.41; P = 0.006) were independently associated with IE. Sensitivity analyses yielded consistent results; also, infection by a member of the mitis group was independent risk factor for IE (aOR, 6.50; 95% CI, 2.87–14.68; P < 0.001). Conclusions: Younger age, heart valve disease, persistent bacteraemia, absence of underlying malignancy and BSI by a member of the mitis group were independent risk factors for IE in patients with VGS BSI. Echocardiographic evaluation could be prudently considered based on these clinicomicrobiological risk factors.
- 8 July 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (9) , 2327-2333
Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia
Background: When to perform echocardiography to rule out infective endocarditis (IE) in patients with viridans group streptococci (VGS) bloodstream infections (BSIs) is unclear. Objectives: We aimed to identify independent risk factors for IE in patients with VGS BSI. Methods: This retrospective study conducted at Seoul National University Hospital from January 2013 to December 2022 involved patients with VGS and nutritionally variant streptococcal BSI, excluding single positive blood cultures and polymicrobial BSI cases. Independent risk factors were identified by multivariate logistic regression and sensitivity analyses according to echocardiography results, VGS species or the inclusion of possible IE cases. Results: Of 845 VGS BSI cases, 349 were analysed and 86 IE cases were identified (24.6%). In the multivariate analysis, heart valve disease [adjusted odds ratio (aOR), 14.14, 95% CI, 6.14–32.58; P < 0.001], persistent bacteraemia (aOR, 5.12, 95% CI, 2.03–12.94; P = 0.001), age (per year, aOR, 0.98; 95% CI, 0.96–1.00; P = 0.015), solid cancer (aOR, 0.26; 95% CI, 0.13–0.53; P < 0.001) and haematologic malignancy (aOR, 0.04; 95% CI, 0.01–0.41; P = 0.006) were independently associated with IE. Sensitivity analyses yielded consistent results; also, infection by a member of the mitis group was independent risk factor for IE (aOR, 6.50; 95% CI, 2.87–14.68; P < 0.001). Conclusions: Younger age, heart valve disease, persistent bacteraemia, absence of underlying malignancy and BSI by a member of the mitis group were independent risk factors for IE in patients with VGS BSI. Echocardiographic evaluation could be prudently considered based on these clinicomicrobiological risk factors.
- Open Access
- 26 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae348
The Microbiological Characteristics of Acinetobacter Baumannii Associated With Early Mortality in Patients With Bloodstream Infection
Despite rapid deaths resulting from Acinetobacter baumannii bacteremia, the clinical impact of the microbiological characteristics of A baumannii strains on early mortality (EM) is unclear. We aimed to identify the microbiological characteristics of A baumannii strains associated with EM. Clinical information and isolates from patients with A baumannii bacteremia from January 2015 to December 2021 were collected. EM was defined as death within 3 days of the initial positive blood culture, whereas late mortality meant death within 5–30 days. The microbiological characteristics of A baumannii were analyzed using multilocus sequence typing, polymerase chain reactions, and a Galleria mellonella in vivo infection model. Among 130 patients, 69 (53.1%) died within 30 days and EM occurred in 38 (55.1% of 30-day deaths). Sequence type 191 (ST191) strain was more prevalent in patients with EM than in 30-day survivors (31.6% vs 6.6%). Regarding virulence genes, bfmS was more frequent (92.1% vs 47.5%), whereas bauA was less frequent (13.2% vs 52.5%) in patients with EM than in 30-day survivors. Higher clinical severity, pneumonia, and ST191 infection were identified as independent risk factors for EM. In the G mellonella infection model, ST191, bfmS+, and bauA– isolates showed higher virulence than non-ST191, bfmS–, and bauA+ isolates, respectively. ST191 and bfmS were more frequently found in the EM group. ST191 infection was also an independent risk factor for EM and highly virulent in the in vivo model. Tailored infection control measures based on these characteristics are necessary for A baumannii bacteremia management.
- 26 June 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae348
Open AccessThe Microbiological Characteristics of Acinetobacter Baumannii Associated With Early Mortality in Patients With Bloodstream Infection
Despite rapid deaths resulting from Acinetobacter baumannii bacteremia, the clinical impact of the microbiological characteristics of A baumannii strains on early mortality (EM) is unclear. We aimed to identify the microbiological characteristics of A baumannii strains associated with EM. Clinical information and isolates from patients with A baumannii bacteremia from January 2015 to December 2021 were collected. EM was defined as death within 3 days of the initial positive blood culture, whereas late mortality meant death within 5–30 days. The microbiological characteristics of A baumannii were analyzed using multilocus sequence typing, polymerase chain reactions, and a Galleria mellonella in vivo infection model. Among 130 patients, 69 (53.1%) died within 30 days and EM occurred in 38 (55.1% of 30-day deaths). Sequence type 191 (ST191) strain was more prevalent in patients with EM than in 30-day survivors (31.6% vs 6.6%). Regarding virulence genes, bfmS was more frequent (92.1% vs 47.5%), whereas bauA was less frequent (13.2% vs 52.5%) in patients with EM than in 30-day survivors. Higher clinical severity, pneumonia, and ST191 infection were identified as independent risk factors for EM. In the G mellonella infection model, ST191, bfmS+, and bauA– isolates showed higher virulence than non-ST191, bfmS–, and bauA+ isolates, respectively. ST191 and bfmS were more frequently found in the EM group. ST191 infection was also an independent risk factor for EM and highly virulent in the in vivo model. Tailored infection control measures based on these characteristics are necessary for A baumannii bacteremia management.